FMP
Creative Medical Technology Holdings, Inc.
CELZ
NASDAQ
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
2.14 USD
0.05 (2.34%)
Historical Prices
From:
To:
About
ceo
Mr. Timothy Warbington
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
CIK
0001187953
ISIN
US22529Y4089
CUSIP
22529Y200
Address
211 East Osborn Road
Phone
480 399 2822
Country
US
Employee
4
IPO Date
Nov 6, 2015
Financial Statement
Earnings
CELZ Financial Summary
CIK
0001187953
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
22529Y200
ISIN
US22529Y4089
Country
US
Price
2.14
Beta
4.85
Volume Avg.
118.26k
Market Cap
5.53M
Shares
-
52-Week
1.69-6.9
DCF
4
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.58
P/B
-
Website
https://www.creativemedicaltechnology.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CELZ News
zacks.com
Mar 25, 2025
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded t...
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Mar 25, 2025
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock O...
Here is how Creative Medical Technology Holdings, Inc. (CELZ) and 89BIO (ETNB) have performed compared to their sector so far this year.
globenewswire.com
Mar 20, 2025
Creative Medical Technology Holdings Secures FDA Clearance f...
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study
globenewswire.com
Mar 6, 2025
Creative Medical Technology Holdings Announces Agreements fo...
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of $4.42 per share. Th...
globenewswire.com
Feb 14, 2025
Creative Medical Technology Holdings Announces Mid-Term Foll...
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing in regenerative medicine solutions for immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced compelling mid-term follow-up data from its StemSpine® pilot study utilizing its AlloStem™ cells for the treatment of chronic lower back pain. The pilot study demonstrated a substan...
globenewswire.com
Feb 11, 2025
Creative Medical Technology Reports Positive One-Year Result...
Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201
globenewswire.com
Feb 5, 2025
Creative Medical Technology Holdings Expands Collaboration w...
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.
globenewswire.com
Jan 30, 2025
Creative Medical Technology Holdings Announces Positive Init...
PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising initial data from the first cohort of its ongoing Phase 1/2 clinical trial of CELZ-201-DDT, the Company's proprietary stem cell-based therapeutic for the treatment of chronic back pain caused by degenerative disc disease (DDD).
